Ken Griffin Xeris Biopharma Holdings, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,000 shares of XERS stock, worth $48,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,000
Previous 96,500
86.53%
Holding current value
$48,750
Previous $275,000
84.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding XERS
# of Institutions
163Shares Held
61.5MCall Options Held
34.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY10.3MShares$38.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$29.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.34MShares$12.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.88MShares$10.8 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $510M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...